Company news
Cervomed Inc. (NASDAQ:CRVO) news
Every Cervomed Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfv...
September 10, 2026
CervoMed to Participate in September Investor Conferences
September 8, 2026
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 10, 2026
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord G...
August 5, 2026
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for T...
August 4, 2026
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy B...
July 15, 2026
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy B...
July 14, 2026
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of...
July 9, 2026
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association Internation...
July 6, 2026
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
June 22, 2026
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
June 18, 2026
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
June 18, 2026
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 12, 2026
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementi...
June 10, 2026
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 18, 2026
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional...
April 22, 2026
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association ...
April 7, 2026
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy...
March 19, 2026
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
March 17, 2026
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
March 12, 2026
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
March 4, 2026
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Late...
February 18, 2026
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in ...
December 4, 2025
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Demen...
December 2, 2025
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Diseas...
November 24, 2025
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 10, 2025
CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
November 4, 2025
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
October 28, 2025
CervoMed to Present at the Emerging Growth Conference
October 20, 2025
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
October 8, 2025
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
October 7, 2025
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
October 2, 2025
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Asso...
September 17, 2025
CervoMed to Participate in Upcoming Investor Conferences
September 3, 2025
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 11, 2025
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 5, 2025
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progress...
July 28, 2025
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
July 24, 2025
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025
July 8, 2025
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
June 10, 2025
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 12, 2025
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
May 7, 2025
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Pres...
April 2, 2025
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Diso...
March 25, 2025
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
March 17, 2025
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia wit...
March 10, 2025
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
January 31, 2025
CervoMed to Present at the 8th International Lewy Body Dementia Conference
January 29, 2025
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2024
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
December 10, 2024